1. Home
  2. OBIO vs NEWT Comparison

OBIO vs NEWT Comparison

Compare OBIO & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • NEWT
  • Stock Information
  • Founded
  • OBIO 2017
  • NEWT 1998
  • Country
  • OBIO United States
  • NEWT United States
  • Employees
  • OBIO N/A
  • NEWT N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • NEWT Major Banks
  • Sector
  • OBIO Health Care
  • NEWT Finance
  • Exchange
  • OBIO Nasdaq
  • NEWT Nasdaq
  • Market Cap
  • OBIO 118.8M
  • NEWT 281.1M
  • IPO Year
  • OBIO N/A
  • NEWT N/A
  • Fundamental
  • Price
  • OBIO $2.96
  • NEWT $11.66
  • Analyst Decision
  • OBIO Strong Buy
  • NEWT Hold
  • Analyst Count
  • OBIO 5
  • NEWT 4
  • Target Price
  • OBIO $14.20
  • NEWT $13.75
  • AVG Volume (30 Days)
  • OBIO 369.1K
  • NEWT 194.0K
  • Earning Date
  • OBIO 08-11-2025
  • NEWT 07-28-2025
  • Dividend Yield
  • OBIO N/A
  • NEWT 6.55%
  • EPS Growth
  • OBIO N/A
  • NEWT 27.62
  • EPS
  • OBIO N/A
  • NEWT 1.92
  • Revenue
  • OBIO $2,886,000.00
  • NEWT $352,584,000.00
  • Revenue This Year
  • OBIO $20.47
  • NEWT N/A
  • Revenue Next Year
  • OBIO $11.45
  • NEWT $13.51
  • P/E Ratio
  • OBIO N/A
  • NEWT $6.03
  • Revenue Growth
  • OBIO 30.23
  • NEWT 23.06
  • 52 Week Low
  • OBIO $2.37
  • NEWT $9.12
  • 52 Week High
  • OBIO $8.87
  • NEWT $15.49
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 51.30
  • NEWT 63.17
  • Support Level
  • OBIO $2.78
  • NEWT $11.60
  • Resistance Level
  • OBIO $2.94
  • NEWT $11.00
  • Average True Range (ATR)
  • OBIO 0.21
  • NEWT 0.31
  • MACD
  • OBIO -0.00
  • NEWT 0.10
  • Stochastic Oscillator
  • OBIO 60.87
  • NEWT 86.39

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About NEWT NewtekOne Inc.

NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.

Share on Social Networks: